Form D · Biotechnology
Reglagene, Inc.
Tucson, AZ · CIK 0001747083
Offering snapshot reported May 21, 2024 · SEC filing
- Reported sold
- $767K Offering amount: $2.5M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- May 16, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 21, 2024 | Initial | $766,655 | No comparison | 12 | SEC filing |
| Nov 21, 2023 | Amendment | $3,794,000 | $2,144,000vs May 17, 2023 | 22 | SEC filing |
| May 17, 2023 | Amendment | $1,650,000 | $1,650,000vs Jul 5, 2022 | 22 | SEC filing |
| Jul 5, 2022 | Initial | $0 | No comparison | 15 | SEC filing |
| Jul 13, 2021 | Initial | $600,000 | No comparison | Not reported | SEC filing |
| Aug 17, 2018 | Initial | $546,413 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513867
Source: Form D, filed May 21, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Austin | Director, Executive |
| Sharon Ayd | Director |
| David J. Bearss | Director |
| Laurence Hurley | Director |
| Lawrence Kinet | Director |
| Ayd Sharon | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3320 N. Campbell Ave., Suite 201
Tucson, AZ, 85719
Tucson, AZ, 85719